Oxford Asset Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Oxford Asset Management’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-20,658	Closed	-$284K	–	2130
2018 Q4	$284K	Sell	20,658 -44,970	-69%	-$567K	0.01%	1422
2018 Q3	$650K	Sell	65,628 -77,160	-54%	-$1.27M	0.01%	1198
2018 Q2	$2.85M	Buy	+142,788	New	+$2.99M	0.05%	442

Other funds holding EIDX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Oxford Asset Management's EIDX Position: Q1 2019 in Review

Oxford Asset Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2019, closing a stake of 20,658 shares — an estimated $284K sold.

Oxford Asset Management first reported a position in EIDX in Q2 2018 and held it in 3 quarters. The position peaked at $2.85M in Q2 2018. 63 funds tracked by Wall St. Rank hold EIDX as of Q1 2019.

Oxford Asset Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Oxford Asset Management sold 20,658 Eidos Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $284K.
Oxford Asset Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 3 quarters.
Oxford Asset Management's Eidos Therapeutics, Inc. Common Stock position peaked at $2.85M in Q2 2018.
63 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.